In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.

Fintel reports that on January 10, 2025, Jefferies downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold. Analyst Price Forecast Suggests 858.18% Upside As of December 23, 2024 ...

Stock tumbles to continue slide that started after the company switched to autoimmunity from oncology late last year IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from $12.00 to $2.00 in a research note issued to investors on Friday,Benzinga ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector perform rating in a report released on Friday, MarketBeat.com reports. The ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...

JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...

MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...